Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

Table 2 Univariate analysis of the clinical parameters for the prediction of progression-free survival

Parameter	n	Univariate analysis
		HR (95%CI)	P value
Sex
Woman	33	1
Man	49	1.37 (0.82-2.3)	0.232
Age (yr)
< 65	41	1
≥ 65	41	0.85 (0.52-1.41)	0.536
Staging
Locally advanced	14	1
Metastatic	68	1.39 (0.68-2.82)	0.367
ECOG performance status score
0-1	70	1
2	12	1.49 (0.77-2.87)	0.234
CA19-9 (IU/mL)
< 1000	48	1
≥ 1000	34	1.33 (0.81-2.21)	0.264
CEA (ng/mL)
< 5	46	1
≥ 5	29	1.24 (0.72-2.13)	0.441
NLR
≤ 5	62	1
> 5	20	1.80 (1.04-3.19)	0.049
PLR
≤ 150	46	1
> 150	36	1.22 (0.73-2.02)	0.448
CRP/albumin ratio
≤ 0.5	42	1
> 0.5	40	1.72 (1.07-2.80)	0.047

ECOG: Eastern Cooperative Oncology Group; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; HR: Hazard ratio.